Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1636 1678 1686
This examiner grants 54% of resolved cases
McKenzie A. Dunn has overseen 80 resolved cases in Art Unit 1632, resulting in an allowance rate of 53.8%. This indicates a moderate level of difficulty for applicants in Tech Center 1600. However, the interview lift of 56.3% is exceptionally high, suggesting that examiner interviews are an extremely effective tool for securing an allowance.
The median days to allowance is 1432, which is a long prosecution cycle. Given the 53.8% baseline allowance rate, the 56.3% lift from interviews is a vital statistic for practitioners to consider. The 1432-day median pendency suggests a long road to allowance, but the effectiveness of interviews provides a clear strategy for success.
With 80 resolved cases, the 53.8% allowance rate is a reliable indicator of the examiner's approach. The 56.3% interview lift is a powerful tool for moving toward a successful outcome. Understanding the 1432-day median pendency allows for better planning and management of the prosecution process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18257838 | ANTITHROMBIN HEPARAN SULFATE FOR DETECTION AND TREATMENT OF CANCER | Final Rejection | The Regents of the University of California |
| 18263899 | METHODS OF ADJUSTING THE PH OF A CELL CULTURE MEDIUM | Non-Final OA | Bayer HealthCare LLC |
| 17798514 | CSF PHOSPHORYLATED TAU AND AMYLOID BETA PROFILES AS BIOMARKERS OF TAUOPATHIES | Final Rejection | Washington University |
| 17422051 | MULTIPLEXED ASSAY AND METHODS OF USE THEREOF | Non-Final OA | Washington University |
| 18048673 | A SYNTHENTIC POLY-TRANSTHYRETIN AFFINITY TRAP FOR DETECTING AMYLOIDOGENIC TRANSTHYRETIN FORMS IN PLASMA SAMPLES OFTRANTHYRETIN AMYLOIDOSIS PATIENTS | Final Rejection | Northwestern University |
| 18541476 | METHOD FOR IMMUNOSENSING ON A LIPID LAYER | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 18426938 | IMMUNOHISTOCHEMISTRY (IHC) MAGE-A4 SCORING PROTOCOLS AND METHODS FOR AIDING CANCER TREATMENTS | Non-Final OA | Agilent Technologies, Inc. |
| 18140177 | PREDICTING IMMUNOTHERAPY RESPONSE | Non-Final OA | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED |
| 17288849 | COMPOSITIONS AND METHODS FOR SELECTING BIALLELIC GENE EDITING | Final Rejection | United States Government As Represented By The Department of Veterans Affairs |
| 18681004 | METHODS FOR SELECTING A CANCER PATIENT FOR TREATMENT | Non-Final OA | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE |
| 18359300 | DETECTION OF AIRBORNE ANALYTES USING IMPRINTED MICELLES | Non-Final OA | Battelle Memorial Institute |
| 15963271 | DIAGNOSING MULTIPLE SCLEROSIS | Final Rejection | Oxford University Innovation Limited |
| 17895953 | TRIAGING METHOD USING CELL FREE NUCLEOSOME LEVELS | Non-Final OA | Belgian Volition SRL (BE/BE) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy